issu
nephron
perico
benigni
remuzzi
offer
concis
overview
interact
viru
angiotensinconvert
enzym
ace
pathway
cell
surfac
glycoprotein
describ
mechan
cellular
uptak
via
endocytosislysosom
pathway
grow
interest
use
prevent
andor
treat
clinic
syndrom
associ
viru
class
drug
ancient
histori
start
record
use
quinin
cutan
lupu
develop
larg
number
congen
includ
chloroquinolin
hydroxyquinolin
malari
prophylaxi
world
war
ii
use
prophylaxi
malaria
appear
involv
endosomallysosom
pathway
lipophil
pk
central
antivir
antibacteri
effect
lay
press
fill
report
antidot
treatment
approach
meant
decreas
sever
mani
includ
uncontrol
fashion
clinicaltrialsgov
list
entri
http
cond
sarscovinfect
draw
rank
trial
yet
recruit
tabl
univers
minnesota
organ
random
placebocontrol
clinic
trial
rct
within
remark
rapid
timefram
initi
post
clinicaltrialsgov
march
activ
recruit
begin
march
singlecent
rct
nationwid
recruit
primari
outcom
measur
trial
includ
incid
activ
diseas
day
postenrol
diseas
sever
scale
selfreport
particip
day
postenrol
diseas
score
diseas
hospit
score
diseas
hospit
death
score
goal
enrol
random
subject
activedrug
placebo
arm
follow
treatment
cours
hydroxychloroquin
secondari
outcom
measur
includ
incid
hospit
incid
confirm
infect
number
particip
arm
discontinu
withdraw
protocol
incid
death
relat
diseas
subject
includ
rct
healthcar
worker
household
contact
expos
diseas
case
within
day
yet
develop
symptom
eg
fever
cough
short
breath
trial
includ
charter
data
safeti
monitor
board
defin
stop
rule
clinic
futil
statist
signific
improv
primari
outcom
measur
compar
activedrug
group
placebo
group
person
commun
march
prophylaxi
faq
account
demonstr
signific
clinic
benefit
hydroxychloroquin
activ
drug
could
offer
subject
origin
random
placebo
group
openlabel
extens
studi
interim
analysi
day
primari
outcom
measur
certainli
feasibl
subject
enrol
treat
result
guid
subsequ
inquiri
would
includ
treatment
activ
compar
arm
rather
placebo
arm
exampl
prophylaxi
period
may
suffici
healthcar
worker
continu
expos
import
lay
public
understand
welldesign
clinic
trial
may
well
pose
mani
new
hypothes
test
test
origin
trial
design
furthermor
stage
set
trial
novel
retrovir
therapi
solubl
act
decoy
receptor
reduc
cellular
uptak
care
robust
trial
design
exemplifi
univers
minnesota
effort
essenti
even
midst
overwhelm
pandem
dr
warnock
relev
conflict
interest
support
uabucsd
obrien
center
acknowledg
